相关实验视频

Updated: May 20, 2025

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

在扩散型大B细胞淋巴瘤中,CA125的预后值

Jie Zhang¹, Yijing Jiang², Long Chen³

¹Department of Oncology, Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu, China.

Frontiers in oncology

|March 24, 2025

概括

诊断时的血清碳水化合物抗原125 (CA125) 水平预测了扩散性大B细胞淋巴瘤 (DLBCL) 的预后. CA125升高表明DLBCL患者的生存结果较差.

科学领域:

在瘤学瘤学.
血液学血液学血液学
临床生物标志物临床生物标志物

背景情况:

碳水化合物抗原125 (CA125) 是固体瘤的瘤生物标志物.
血清CA125与非霍奇金淋巴瘤的预后有相关性.

研究的目的:

调查CA125在扩散性大B细胞淋巴瘤 (DLBCL) 的临床意义.

主要方法:

对315名新诊断的DLBCL患者的回顾性分析.
血清CA125与临床病理学参数的相关性分析.
卡普兰-梅尔生存分析,考克斯比例危险模型和免疫组织化学.

主要成果:

血清CA125升高 (26%的患者) 与表现不佳,晚期,B型症状,体积大,排泄,高IPI,高LDH和低专相关.
升高的CA125与较短的无进展生存期 (PFS) 和整体生存期 (OS) 相相关.
CA125,起源细胞,IPI和白蛋白是OS和PFS的独立预后因素;DLBCL组织中没有发现CA125表达.

结论:

最初诊断时的血清CA125是DLBCL患者预后的重要预测因素.

关键词:

生物标志物生物标志物碳水化合物抗原125 碳水化合物抗原125 扩散大的B细胞淋巴瘤.总体存活率总体存活率预后预后预后没有进展的生存率.

更多相关视频

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...